What is the ticker symbol for Cellectar Biosciences?

Cellectar Biosciences trades under the ticker CLRB on NASDAQ.

What sector does Cellectar Biosciences operate in?

Cellectar Biosciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CLRB in a portfolio?

PortView shows CLRB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Cellectar Biosciences (CLRB) Stock Analysis

NASDAQHealthcareBiotechnology

$2.49+1.22%

1-year price historyRange $2.23 – $6.17

52-week range$2.49

$2.20$6.52

What Cellectar Biosciences does

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.

Key metrics

Market cap

$19.90M

P/E (TTM)

-0.37

EPS (TTM)

$-6.66

Beta

0.56

Dividend yield

0.00%

Revenue / share

$0.00

50-day avg

$2.58

200-day avg

$2.94

52-week high

$6.52

52-week low

$2.20

CEO

James V. Caruso

ETFs linked to CLRB

Broad-market and Healthcare sector ETFs an investor holding Cellectar Biosciences is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how CLRB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze CLRB in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Cellectar Biosciences?: Cellectar Biosciences trades under the ticker CLRB on NASDAQ.
Which exchange is CLRB listed on?: CLRB is listed on NASDAQ.
What sector does Cellectar Biosciences operate in?: Cellectar Biosciences is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze CLRB in a portfolio?: PortView shows CLRB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.